

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

CLARIFICATION ANNOUNCEMENT GRANT OF RESTRICTED SHARES

Reference is made to the announcement of Innovent Biologics, Inc. (the “**Company**”) dated March 24, 2024 (the “**Announcement**”) in relation to, among others, the grant of restricted shares by the Company to non-connected employees of the Group (the “**RS Grants**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless the context otherwise requires.

The Board would like to clarify that, due to an inadvertent clerical error, the vesting period for the RS Grants as mentioned in the Announcement should be 75% shall vest on March 22, 2027, and 25% shall vest on March 22, 2028, instead of 33.33% shall vest on March 22, 2025, 33.33% shall vest on March 22, 2026, and 33.33% shall vest on March 22, 2027.

Save as disclosed in this announcement, all information set out in the Announcement remains unchanged.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China, April 3, 2024

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen, Mr. Gary Zieziula and Dr. Shun Lu as Independent Non-executive Directors.